Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma



: Edqvist PHD, Huvila J, Forsstrom B, Talve L, Carpen O, Salvesen HB, Krakstad C, Grenman S, Johannesson H, Ljungqvist O, Uhlen M, Ponten F, Auranen A

Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE

: 2015

: Gynecologic Oncology

: GYNECOLOGIC ONCOLOGY

: GYNECOL ONCOL

: 137

: 3

: 529

: 537

: 9

: 0090-8258

DOI: https://doi.org/10.1016/j.ygyno.2015.03.055(external)


Conclusions. Loss of ASRGL1 in EEA is a powerful biomarker for poor prognosis and retained ASRGL1 has a positive impact on survival. ASRGL1 immunohistochemistry has potential to become an additional tool for prognostication in cases where tailoring adjuvant treatment according to additional prognostic factors besides grade and stage is recommended. (C) 2015 Elsevier Inc. All rights reserved.




Last updated on 2024-26-11 at 12:20